Evidence map›Paper›PMID 22924544›Full record

ArticleBritish journal of haematology2012

Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.

Zheng Chen, Jorge Romaguera, Michael Wang, Luis Fayad, Larry W Kwak, Nami McCarty

Open access · bronzeAbstract readLetter
In one paragraph

Article in British journal of haematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zheng Chen
Jorge Romaguera
Michael Wang
Luis Fayad
Larry W Kwak
Nami McCarty
The University of Texas MD Anderson Cancer Center · USBrown Foundation · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
U OF TEXAS HLTH SCI CTR HOUSTON CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCESUL1RR024148 · NCRR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2006 to 2010
$27.9M
UT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2009 to 2011
$1.5M
Characterizing Clonogenic Populations in Mantle Cell LymphomaR21CA141275 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCCARTY, NAMI · 2010 to 2011
$353k
NCI NIH HHS CA16672NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA136411NCI NIH HHS P50CA136411NCI NIH HHS R21 CA141275NCRR NIH HHS UL1 RR024148
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsBoronic AcidsBortezomibDrug SynergismFemaleHumansLymphoma, Mantle-CellMalePyrazinesReactive Oxygen SpeciesTumor Cells, CulturedVasodilator AgentsVerapamilAntineoplastic AgentsBoronic AcidsBortezomibPyrazinesReactive Oxygen SpeciesVasodilator AgentsVerapamil

Identifiers

PMID22924544
PMCPMC3460105
OpenAlexW2031726846

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.